Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20

19 ANTIPSYCHOTICS/NEUROLEPTICS Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of expected to increase these antipsychotic boosted PREZISTA and quetiapine plasma concentrations. is contraindicated as it may (CYP3A inhibition) increase quetiapine-related toxicity. Increased concentrations of quetiapine may lead to coma (see section 4.3). Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for Risperidone expected to increase these antipsychotic these drugs when co-administered Thioridazine plasma concentrations. with boosted PREZISTA. (CYP3A, CYP2D6 and/or P-gp Lurasidone inhibition) Concomitant administration of Pimozide boosted PREZISTA and Sertindole lurasidone, pimozide or sertindole is contraindicated (see section 4.3). β-BLOCKERS Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is Metoprolol expected to increase these β-blocker recommended when Timolol plasma concentrations. co-administering boosted (CYP2D6 inhibition) PREZISTA with β-blockers. A lower dose of the β-blocker should be considered. CALCIUM CHANNEL BLOCKERS Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic Diltiazem expected to increase the plasma and adverse effects is Felodipine concentrations of calcium channel recommended when these Nicardipine blockers. medicines are concomitantly Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted Verapamil PREZISTA. CORTICOSTEROIDS Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all (including were co-administered with 50 g routes of administration) that are betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects, triamcinolone) concentrations increased significantly, including Cushing’s syndrome and whereas the intrinsic cortisol levels adrenal suppression. decreased by approximately 86% (90% CI 82-89%). Greater effects may be Co-administration with CYP3A- expected when fluticasone is inhaled. metabolised corticosteroids is not Systemic corticosteroid effects including recommended unless the potential Cushing’s syndrome and adrenal benefit to the patient outweighs the suppression have been reported in risk, in which case patients should patients receiving ritonavir and inhaled or be monitored for systemic intranasally administered fluticasone. The corticosteroid effects. effects of high fluticasone systemic exposure on ritonavir plasma levels are Alternative corticosteroids which unknown. are less dependent on CYP3A metabolism e.g. beclomethasone Other corticosteroids: interaction not should be considered, particularly studied. Plasma concentrations of these for long term use. medicinal products may be increased when co-administered with boosted PREZISTA, resulting in reduced serum cortisol concentrations. Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should (systemic) decrease plasma concentrations of be used with caution when darunavir. combined with boosted (CYP3A induction) PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62

HOS-116527 · Präparat HOS-094447

61 Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for Risperidone increase these antipsychotic plasma these drugs when co-administered Thioridazine concentrations. with PREZISTA co-administered (CYP3A, CYP2D6 and/or P-gp with low dose ritonavir. inhibition) Lurasidone Concomitant administration of Pimozide PREZISTA with low dose Sertindole ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3). β-BLOCKERS Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is Metoprolol increase these β-blocker plasma recommended when Timolol concentrations. co-administering PREZISTA with (CYP2D6 inhibition) β-blockers. A lower dose of the β-blocker should be considered. CALCIUM CHANNEL BLOCKERS Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic Diltiazem with low dose ritonavir can be expected and adverse effects is Felodipine to increase the plasma concentrations of recommended when these Nicardipine calcium channel blockers. medicines are concomitantly Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with Verapamil low dose ritonavir. CORTICOSTEROIDS Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and (including were co-administered with 50 g corticosteroids (all routes of betamethasone, intranasal fluticasone propionate (4 times administration) that are budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may mometasone, prednisone, fluticasone propionate plasma increase the risk of development of triamcinolone) concentrations increased significantly, systemic corticosteroid effects, whereas the intrinsic cortisol levels including Cushing’s syndrome and decreased by approximately 86% (90% adrenal suppression. CI 82-89%). Greater effects may be expected when fluticasone is inhaled. Co-administration with CYP3A- Systemic corticosteroid effects including metabolised corticosteroids is not Cushing’s syndrome and adrenal recommended unless the potential suppression have been reported in benefit to the patient outweighs the patients receiving ritonavir and inhaled or risk, in which case patients should intranasally administered fluticasone. The be monitored for systemic effects of high fluticasone systemic corticosteroid effects. exposure on ritonavir plasma levels are unknown. Alternative corticosteroids which are less dependent on CYP3A Other corticosteroids: interaction not metabolism e.g. beclomethasone studied. Plasma concentrations of these should be considered, particularly medicinal products may be increased for long term use. when co-administered with PREZISTA with low dose ritonavir, resulting in reduced serum cortisol concentrations. Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should (systemic) decrease plasma concentrations of be used with caution when darunavir. combined with PREZISTA (CYP3A induction) co-administered with low dose ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102

HOS-116617 · Präparat HOS-094447

101 ANTIPSYCHOTICS/NEUROLEPTICS Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of expected to increase these antipsychotic boosted PREZISTA and quetiapine plasma concentrations. is contraindicated as it may (CYP3A inhibition) increase quetiapine-related toxicity. Increased concentrations of quetiapine may lead to coma (see section 4.3). Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for Risperidone expected to increase these antipsychotic these drugs when co-administered Thioridazine plasma concentrations. with boosted PREZISTA. (CYP3A, CYP2D6 and/or P-gp Lurasidone inhibition) Concomitant administration of Pimozide boosted PREZISTA and Sertindole lurasidone, pimozide or sertindole is contraindicated (see section 4.3). β-BLOCKERS Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is Metoprolol expected to increase these β-blocker recommended when Timolol plasma concentrations. co-administering boosted (CYP2D6 inhibition) PREZISTA with β-blockers. A lower dose of the β-blocker should be considered. CALCIUM CHANNEL BLOCKERS Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic Diltiazem expected to increase the plasma and adverse effects is Felodipine concentrations of calcium channel recommended when these Nicardipine blockers. medicines are concomitantly Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted Verapamil PREZISTA. CORTICOSTEROIDS Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all (including were co-administered with 50 g routes of administration) that are betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects, triamcinolone) concentrations increased significantly, including Cushing’s syndrome and whereas the intrinsic cortisol levels adrenal suppression. decreased by approximately 86% (90% CI 82-89%). Greater effects may be Co-administration with CYP3A- expected when fluticasone is inhaled. metabolised corticosteroids is not Systemic corticosteroid effects including recommended unless the potential Cushing’s syndrome and adrenal benefit to the patient outweighs the suppression have been reported in risk, in which case patients should patients receiving ritonavir and inhaled or be monitored for systemic intranasally administered fluticasone. The corticosteroid effects. effects of high fluticasone systemic exposure on ritonavir plasma levels are Alternative corticosteroids which unknown. are less dependent on CYP3A metabolism e.g. beclomethasone Other corticosteroids: interaction not should be considered, particularly studied. Plasma concentrations of these for long term use. medicinal products may be increased when co-administered with boosted PREZISTA, resulting in reduced serum cortisol concentrations. Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should (systemic) decrease plasma concentrations of be used with caution when darunavir. combined with boosted (CYP3A induction) PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt

Wechselwirkungen · Farydak

Farydak 10 mg hard capsules Farydak 15 mg hard capsules Farydak 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12

HOS-130458 · Präparat HOS-096923

Panobinostat increased the Cmax and the AUC of dextromethorphan (a substrate of CYP2D6) by 1.8- and 1.6-fold, respectively, and it cannot be excluded that the effect may be larger on a more sensitive CYP2D6 substrate. Avoid panobinostat use in patients who are taking CYP2D6 substrates with a narrow therapeutic index (including, but not limited to, pimozide). When Farydak is co-administered with sensitive CYP2D6 substrates (e.g. atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine and pimozide), dose titrate individual CYP2D6 substrates based on tolerability and frequently monitor patients for adverse reactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nebivolol (HOS-130459) atomoxetine (HOS-130436) perphenazine (HOS-116395) panobinostat (HOS-130447) pimozide (HOS-085600) dextromethorphan (HOS-109265) metoprolol (HOS-090094)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-01T17:42:00Z · SHA-256 58ca307f8694fb48a8bc74d8804d492564d6c11554c366f3220bc8e9fa2ab9be · Passage f7ad5b101ab18a174bbb416a6db89510d897b953d57589a4b7201ae26b46ae8d · Zeichen 1927–2559 im Abschnitt

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18

HOS-134507 · Präparat HOS-097580

17 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Geometric mean change Recommendations concerning co- therapeutic areas (%) administration Perphenazine Not studied. Darunavir is expected to A dose decrease may be needed for Risperidone increase these antipsychotic plasma these drugs when co-administered Thioridazine concentrations. with darunavir co-administered with (CYP3A, CYP2D6 and/or P-gp low dose ritonavir. inhibition) Lurasidone Pimozide Concomitant administration of Sertindole darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3). β-BLOCKERS Carvedilol Not studied. Darunavir is expected to Clinical monitoring is Metoprolol increase these β-blocker plasma recommended when co- Timolol concentrations. administering darunavir with β- (CYP2D6 inhibition) blockers. A lower dose of the β- blocker should be considered. CALCIUM CHANNEL BLOCKERS Amlodipine Not studied. Darunavir co-administered Clinical monitoring of therapeutic Diltiazem with low dose ritonavir can be and adverse effects is recommended Felodipine expected to increase the plasma when these medicines are Nicardipine concentrations of calcium channel concomitantly administered with Nifedipine blockers. darunavir with low dose ritonavir. Verapamil (CYP3A and/or CYP2D6 inhibition) CORTICOSTEROIDS Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of darunavir with metabolised by CYP3A ritonavir 100 mg capsules twice daily low dose ritonavir and (including betamethasone, were co-administered with 50 μg corticosteroids (all routes of budesonide, fluticasone, intranasal fluticasone propionate (4 administration) that are metabolised mometasone, prednisone, times daily) for 7 days in healthy by CYP3A may increase the risk of triamcinolone) subjects, fluticasone propionate plasma development of systemic concentrations increased significantly, corticosteroid effects, including whereas the intrinsic cortisol levels Cushing’s syndrome and adrenal decreased by approximately 86% (90% suppression. CI 82-89%). Greater effects may be expected when fluticasone is inhaled. Co-administration with CYP3A- Systemic corticosteroid effects metabolised corticosteroids is not including Cushing’s syndrome and recommended unless the potential adrenal suppression have been reported benefit to the patient outweighs the in patients receiving ritonavir and risk, in which case patients should inhaled or intranasally administered be monitored for systemic fluticasone. The effects of high corticosteroid effects. fluticasone systemic exposure on ritonavir plasma levels are unknown. Alternative corticosteroids which are less dependent on CYP3A Other corticosteroids: interaction not metabolism e.g. beclomethasone studied. Plasma concentrations of these should be considered, particularly medicinal products may be increased for long term use. when co-administered with darunavir with low dose ritonavir, resulting in reduced serum cortisol concentrations. Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be decrease plasma concentrations of used with caution when combined darunavir. (CYP3A induction) with darunavir co-administered with low dose ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4d699252eaa8e454816efcf834725c875d4dc8037df504e7418d309238a96785 · Zeichen 43154–48076 im Abschnitt

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60

HOS-134627 · Präparat HOS-097580

59 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Recommendations concerning co- therapeutic areas Geometric mean change (%) administration Perphenazine Not studied. Boosted darunavir is A dose decrease may be needed for Risperidone expected to increase these these drugs when co-administered Thioridazine antipsychotic plasma with boosted darunavir. concentrations. (CYP3A, CYP2D6 and/or P-gp inhibition) Lurasidone Concomitant administration of Pimozide boosted darunavir and lurasidone, Sertindole pimozide or sertindole is contraindicated (see section 4.3). β-BLOCKERS Carvedilol Not studied. Boosted darunavir is Clinical monitoring is recommended Metoprolol expected to increase these β-blocker when co-administering boosted Timolol plasma concentrations. darunavir with β-blockers. A lower (CYP2D6 inhibition) dose of the β-blocker should be considered. CALCIUM CHANNEL BLOCKERS Amlodipine Not studied. Boosted darunavir can Clinical monitoring of therapeutic Diltiazem be expected to increase the plasma and adverse effects is recommended Felodipine concentrations of calcium channel when these medicines are Nicardipine blockers. concomitantly administered with Nifedipine (CYP3A and/or CYP2D6 boosted darunavir. Verapamil inhibition) CORTICOSTEROIDS Corticosteroids primarily Fluticasone: in a clinical study Concomitant use of boosted metabolised by CYP3A where ritonavir 100 mg capsules darunavir and corticosteroids (all (including betamethasone, twice daily were co-administered routes of administration) that are budesonide, fluticasone, with 50 μg intranasal fluticasone metabolised by CYP3A may increase mometasone, prednisone, propionate (4 times daily) for 7 the risk of development of systemic triamcinolone) days in healthy subjects, fluticasone corticosteroid effects, including propionate plasma concentrations Cushing’s syndrome and adrenal increased significantly, whereas the suppression. intrinsic cortisol levels decreased by approximately 86% (90% CI 82- Co-administration with CYP3A- 89%). Greater effects may be metabolised corticosteroids is not expected when fluticasone is recommended unless the potential inhaled. Systemic corticosteroid benefit to the patient outweighs the effects including Cushing's risk, in which case patients should be syndrome and adrenal suppression monitored for systemic corticosteroid have been reported in patients effects. receiving ritonavir and inhaled or intranasally administered Alternative corticosteroids which are fluticasone. The effects of high less dependent on CYP3A fluticasone systemic exposure on metabolism ritonavir plasma levels are e.g. beclomethasone should be unknown. considered, particularly for long term use. Other corticosteroids: interaction not studied. Plasma concentrations of these medicinal products may be increased when co-administered with boosted darunavir, resulting in reduced serum cortisol concentrations. Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be decrease plasma concentrations of used with caution when combined darunavir. with boosted darunavir. (CYP3A induction)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 5be93392fc9daddc5a4bddcaf5177effda2055057fdf350b6c14c2d3c31e17fc · Zeichen 49576–54404 im Abschnitt

Wechselwirkungen · Symtuza

Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14

HOS-138489 · Präparat HOS-098200

13 ANTIPSYCHOTICS/NEUROLEPTICS Perphenazine Based on theoretical considerations Clinical monitoring is Risperidone DRV/COBI is expected to increase recommended when Thioridazine these neuroleptic plasma co-administering Symtuza with concentrations. perphenazine, risperidone or (CYP3A, CYP2D6 and/or P-gp thioridazine. For these inhibition) neuroleptics, consider reducing the dose of the neuroleptic upon co-administration with Symtuza.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) thioridazine (HOS-086281) perphenazine (HOS-116395)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage b2135cf301bb2a290d08ffd07cf40e612721964164a091bff5b323d07f0ed9e3 · Zeichen 23766–24577 im Abschnitt

Quellenpassagen (7)

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Farydak

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Wechselwirkungen · Symtuza